

**DRG® IL-6 ELISA (EIA- 4640)****REVISED 1 MAR. 2010 RM (VERS. 2.0)****RUO IN THE USA**

*Please use only the valid version of the package insert provided with the kit.*

**1 INTENDED USE**

Immunoenzymetric assay for the in vitro quantitative measurement of human interleukin-6 (IL-6) in serum.

**2 CLINICAL BACKGROUND****2.1 Biological activities**

Human Interleukin 6 (IL-6) is a 184 A.A. polypeptide with potential O and N-glycosylation sites, and a significant homology with G-CSF. It is produced by various cells, including T- and B-cells, monocytes, fibroblasts, keratinocytes, endothelial cells, mesangial cells, astrocytes, bone marrow stroma cells and several tumor cells. It regulates the growth and differentiation of various cell types with major activities on the immune system, hematopoiesis, and inflammation. These multiple actions are integrated within a complex cytokine network, where several cytokines induce (IL-1, TNF, PDGF, IFNs,...) or are induced by IL-6 and the final effects result from either synergistic or antagonistic activities between IL-6 and the other cytokines (IL-1, IL-2, IL-4, IL-5, IFN $\gamma$ , IL-3, GM-CSF, M-CSF, CSF,...). IL-6 induces final maturation of B-cells into antibody producing cells and is a potent growth factor for myeloma/plasmacytoma cells. It (co-) stimulates T-cell growth and cytotoxic T-cell differentiation. It promotes megakaryocyte development and synergizes with other cytokines to stimulate multipotent hematopoietic progenitors. It can also induce differentiation and growth inhibition of some leukemia -or non hematopoietic tumoral cell lines. IL-6 is also a major inducer of the acute phase reactions in response to inflammation or tissue injury. Along with IL-1 and TNF, it induces the synthesis of acute phase proteins (APP) by hepatocytes, each cytokine or combination of cytokines showing a preferential pattern of APP production. IL-6 also interacts with the neuroendocrine system, e.g. by inducing ACTH production. Thus, IL-6 is a pleiotropic cytokine with multiple endocrine, paracrine and possibly autocrine activities in various tissues.

**2.2 Clinical application**

Although most normal controls have undetectable levels of IL-6 in their serum, huge quantities of IL-6 are detected in severe inflammatory situations such as septicemia. The elevation of serum IL-6 precedes that of acute phase proteins, e.g. in a postoperative phenomenon, and may thus be a sensitive early parameter to investigate inflammatory conditions. Serum IL-6 has already been described in association with surgical or traumatic tissue injuries, infectious diseases, auto-immune diseases including arthritis, graft rejection, alcoholic liver cirrhosis, malignancies, etc..



## **DRG® IL-6 ELISA (EIA- 4640)**

**REVISED 1 MAR. 2010 RM (VERS. 2.0)**

**RUO IN THE USA**

### **3 PRINCIPLES OF THE METHOD**

The DRG IL-6-ELISA is a solid phase Enzyme Amplified Sensitivity Immunoassay performed on microtiterplate. The assay uses monoclonal antibodies (MAbs) directed against distinct epitopes of IL-6. Calibrators and samples react with the capture monoclonal antibody (MAb 1) coated on microtiter well and with a monoclonal antibody (MAb 2) labelled with horseradish peroxidase (HRP). After an incubation period allowing the formation of a sandwich: coated MAb 1 – human IL-6 – MAb 2 – HRP, the microtiterplate is washed to remove unbound enzyme labelled antibody. Bound enzyme-labelled antibody is measured through a chromogenic reaction. Chromogenic solution (TMB) is added and incubated. The reaction is stopped with the addition of Stop Solution and the microtiterplate is then read at the appropriate wavelength. The amount of substrate turnover is determined colourimetrically by measuring the absorbance, which is proportional to the IL-6 concentration.


A calibration curve is plotted and IL-6 concentration in samples is determined by interpolation from the calibration curve. The use of the EASIA reader (linearity up to 3 OD units) and a sophisticated data reduction method (polychromatic data reduction) result in a high sensitivity in the low range and in an extended calibration range.

## DRG® IL-6 ELISA (EIA- 4640)

REVISED 1 MAR. 2010 RM (VERS. 2.0)

**RUO** IN THE USA

### 4 REAGENTS PROVIDED

Reagents		96 tests Kit	Color Code	Reconstitution
<b>Microtiterplate</b> with 96 anti IL-6 (monoclonal antibodies) coated wells		96 wells	blue	Ready for use
<b>Conjugate:</b> HRP labelled anti-IL-6 (monoclonal antibodies) in Borate buffer with bovine serum albumin and thymol	<b>Ab HRP</b>	1 vial 11 ml	red	Ready for use
<b>Calibrator</b> N = 0 to 5 (see exact values on vial labels) in human serum with bovine serum albumin, benzamidine and thymol	<b>CAL N</b>	6 vials lyophil.	yellow	Add 1 ml distilled water
<b>Specimen Diluent:</b> human serum with bovine serum albumin, benzamidine and thymol	<b>DIL SPE</b>	3 vials lyophil.	black	Add distilled water (see on the label for the exact volume)
<b>Incubation buffer:</b> Borate buffer with bovine serum albumin, benzamidine and thymol	<b>INC BUF</b>	1 vial 11 ml	black	Ready for use
<b>Wash Solution</b> conc. (Tris-HCl)	<b>WASH SOLN CONC</b>	1 vial 10 ml	brown	Dilute 200 x with distilled water (use a magnetic stirrer).
<b>Control</b> - N = 1 or 2 in human serum with thymol	<b>CONTROL N</b>	2 vials lyophil.	silver	Add 1 ml distilled water
<b>Chromogenic TMB Solution</b>	<b>CHROM TMB</b>	1 vial 25 ml	white	Ready for use
<b>Stop Solution:</b> HCl, 2 N	<b>STOP SOLN</b>	1 vial 25 ml	white	Ready for use

Note: 1. Use Specimen Diluent for sample dilutions.

2. 1 pg of the calibrator preparation is equivalent to 100 mIU of the NIBSC 1<sup>st</sup> IS 89/548.

### 5 SUPPLIES NOT PROVIDED

The following material is required but not provided in the kit:

1. High quality distilled water
2. Pipettes for delivery of: 50 µl, 100 µl, 200 µl, 1 ml and 10 ml (the use of accurate pipettes with disposable plastic tips is recommended)
3. Vortex mixer
4. Magnetic stirrer
5. Horizontal microtiterplate shaker capable of 700 rpm ± 100 rpm

**DRG<sup>®</sup> IL-6 ELISA (EIA- 4640)****REVISED 1 MAR. 2010 RM (VERS. 2.0)****RUO IN THE USA**

6. Washer for Microtiterplates
7. Microtiterplate reader capable of reading at 450 nm, 490 nm and 650 nm (in case of polychromatic reading) or capable of reading at 450 nm and 650 nm (bichromatic reading)
8. Optional equipment: The ELISA-AID<sup>™</sup> necessary to read the plate according to polychromatic reading (see paragraph 10.1.) can be purchased from Robert Maciels Associates, Inc. Mass. 0.2174 USA.

**6 REAGENT PREPARATION****Calibrators:**

Reconstitute the calibrators with 1 ml distilled water.

**Controls:**

Reconstitute the controls with 1 ml distilled water.

**Specimen Diluent:**

Reconstitute Specimen Diluent to the volume specified on the vial label with distilled water

**Working Wash solution:**

Prepare an adequate volume of Working Wash solution by adding 199 volumes of distilled water to 1 volume of Wash Solution (200x). Use a magnetic stirrer to homogenize. Discard unused Working Wash solution at the end of the day.

**7 STORAGE AND EXPIRATION DATING OF REAGENTS**

- Before opening or reconstitution, all kits components are stable until the expiry date, indicated on the vial label, if kept at 2 to 8°C.
- Unused strips must be stored, at 2-8°C, in a sealed bag containing a desiccant until expiration date.
- After reconstitution, calibrators, controls and specimen Diluent are stable for 4 days at 2 to 8°C. For longer storage periods, aliquots should be made and kept at -20°C for maximum 2 months. Avoid successive freeze thaw cycles.
- The concentrated Wash Solution is stable at room temperature until expiration date.
- Freshly prepared Working Wash solution should be used on the same day.
- After its first use, the conjugate is stable until expiry date, if kept in the original well-closed vial at 2 to 8°C.
- Alterations in physical appearance of kit reagents may indicate instability or deterioration.

**8 SPECIMEN COLLECTION AND PREPARATION**

Serum must be removed as soon as possible from the clot of red cells after clotting and centrifugation, and kept at 4°C. If the samples are not used immediately, they must be kept at -20°C for maximum 2 months, and at -70°C for longer storage (maximum one year).

Avoid subsequent freeze thaw cycles.

Prior to use, all samples should be at room temperature. It is recommended to vortex the samples before use.

Sampling conditions can affect values, therefore, strict precautions have to be taken during sampling to avoid impurities contained in sampling materials that would stimulate IL-6 production by blood cells and thus falsely increase plasma IL-6 values.

## DRG® IL-6 ELISA (EIA- 4640)

REVISED 1 MAR. 2010 RM (VERS. 2.0)

**RUO** IN THE USA

Collection tubes must be pyrogen-free.

### 9 PROCEDURE

#### 9.1 Handling notes

Do not use the kit or components beyond expiry date.

Do not mix materials from different kit lots.

Bring all the reagents to room temperature prior to use.

Thoroughly mix all reagents and samples by gentle agitation or swirling.

Perform calibrators, controls and samples in duplicate. Vertical alignment is recommended.

Use a clean plastic container to prepare the Wash Solution.

In order to avoid cross-contamination, use a clean disposable pipette tip for the addition of each reagent and sample.

For the dispensing of the Chromogenic Solution and the Stop Solution avoid pipettes with metal parts.

High precision pipettes or automated pipetting equipment will improve the precision.

Respect the incubation times.

To avoid drift, the time between pipetting of the first calibrator and the last sample must be limited to the time mentioned in section *Time delay*.

Prepare a calibration curve for each run, do not use data from previous runs.

Dispense the Chromogenic Solution within 15 minutes following the washing of the microtiterplate.

During incubation with Chromogenic Solution, avoid direct sunlight on the microtiterplate.

#### 9.2 Procedure

1. Select the required number of strips for the run. The unused strips should be resealed in the bag with a desiccant and stored at 2-8°C.
2. Secure the strips into the holding frame.
3. Pipette 50 µl of Incubation Buffer into all the wells
4. Pipette 100 µl of each Calibrator, Control and Sample into the appropriate wells.
5. Incubate for 1 hour at room temperature on a horizontal shaker set at 700 rpm  $\pm$  100 rpm.
6. Aspirate the liquid from each well.
7. Wash the plate 3 times by:  
Dispensing 0.4 ml of Wash Solution into each well  
Aspirating the content of each well
8. Pipette 100 µl of anti-IL-6-HRP conjugate and 50 µl specimen diluent into all the wells.
9. Incubate for 1 hour at room temperature on a horizontal shaker set at 700 rpm  $\pm$  100 rpm.
10. Aspirate the liquid from each well.

## DRG® IL-6 ELISA (EIA- 4640)

REVISED 1 MAR. 2010 RM (VERS. 2.0)

**RUO** IN THE USA

11. Wash the plate 3 times by:  
Dispensing 0.4 ml of Wash Solution into each well  
Aspirating the content of each well
12. Pipette 200 µl of the Chromogenic Solution into each well within 15 minutes following the washing step.
13. Incubate the microtiterplate for 15 minutes at room temperature on a horizontal shaker set at 700 rpm  $\pm$  100 rpm, avoid direct sunlight.
14. Pipette 100 µl of Stop Solution into each well.
15. Read the absorbencies at 450 nm and 490 nm (reference filter 630 nm or 650 nm) within 3 hours and calculate the results as described in section 10.

## 10 CALCULATION OF RESULTS

### 10.1 Polychromatic Reading:

1. In this case, the ELISA-AID™ software will do the data processing.
2. The plate is first read at 450 nm against a reference filter set at 650 nm (or 630 nm).
3. A second reading is performed at 490 nm against the same reference filter.
4. The ELISA-AID™ Software will drive the reader automatically and will integrate both readings into a polychromatic model. This technique can generate OD's up to 10.
5. The principle of polychromatic data processing is as follows:  
 $X_i = \text{OD at 450 nm}$   
 $Y_i = \text{OD at 490 nm}$   
Using a calibrator unweighted linear regression, the parameters A & B are calculated :  $Y = A \cdot X + B$   
If  $X_i < 3$  OD units, then  $X \text{ calculated} = X_i$   
If  $X_i > 3$  OD units, then  $X \text{ calculated} = (Y_i - B) / A$   
A 4-parameter logistic curve fitting is used to build up the calibration curve.  
The IL-6 concentration in samples is determined by interpolation on the calibration curve.

### 10.2 Bichromatic Reading

1. Read the plate at 450 nm against a reference filter set at 650 nm (or 630 nm).
2. Calculate the mean of duplicate determinations.
3. On semi-logarithmic or linear graph paper plot the OD values (ordinate) for each calibrator against the corresponding concentration of IL-6 (abscissa) and draw a calibration curve through the calibrator points by connecting the plotted points with straight lines.
4. Read the concentration for each control and sample by interpolation on the calibration curve.
5. Computer assisted data reduction will simplify these calculations. If automatic result processing is used, a 4-parameter logistic function curve fitting is recommended.

## DRG® IL-6 ELISA (EIA- 4640)

REVISED 1 MAR. 2010 RM (VERS. 2.0)

**RUO** IN THE USA

### 11 TYPICAL DATA

The following data are for illustration only and should never be used instead of the real time calibration curve.

IL-6-ELISA		OD units Polychromatic model
Standard	0 pg/ml	79
	23.3 pg/ml	125
	68 pg/ml	193
	201 pg/ml	408
	633 pg/ml	1036
	2560 pg/ml	3579

### 12 PERFORMANCE AND LIMITATIONS

#### 12.1 Detection Limit

Twenty zero calibrators were assayed along with a set of other calibrators. The detection limit, defined as the apparent concentration two calibrator deviations above the average OD at zero binding, was 2 pg/ml.

#### 12.2 Specificity

No significant cross-reaction was observed in presence of 50 ng of IL-1 $\alpha$ , IL-1 $\beta$ , IL-2, IL-3, IL-4, IL-7, IL-8, IL-10, GM-CSF, IFN- $\alpha$ , IFN- $\gamma$ , LIF, MIP-1 $\alpha$ , MIP-1 $\beta$ , MCP-1, OSM, RANTES, TGF- $\beta$ , TNF- $\alpha$  and TNF- $\beta$ .

A very tenuous cross-reaction (0.06%) is observed with G-CSF.

#### Interference with the soluble Receptors (sIL6R and sgp-130)

No significant cross-reaction was observed in presence of 100 ng of sIL6 Receptor and sgp-130.

IL6 conc. (pg/ml)	IL6 measured with 100 ng/ml of sIL6R (pg/ml)	IL6 measured with 100 ng/ml of sgp-130 (pg/ml)
7.5	4.3	8.3
74.0	81.8	76.0
678.0	734.0	671.0

No interference was observed.

#### 12.3 Precision

INTRA ASSAY				INTER ASSAY			
Serum	N	<X> $\pm$ SD (pg/ml)	CV (%)	Serum	N	<X> $\pm$ SD (pg/ml)	CV (%)
A	20	147 $\pm$ 6,1	4.2	A	20	114 $\pm$ 5	4.4
B	20	623 $\pm$ 27	4.3	B	20	270 $\pm$ 15	5.4

SD: Standard Deviation; CV: Coefficient of variation

## DRG® IL-6 ELISA (EIA- 4640)

REVISED 1 MAR. 2010 RM (VERS. 2.0)

**RUO** IN THE USA

### 12.4 Accuracy

#### RECOVERY TEST

Sample	Added IL-6 (pg/ml)	Recovered IL-6 (pg/ml)	Recovery (%)
Serum 1	1066	1035	97.1
	547	541	98.9
	228	234	102.6
Serum 2	1066	1110	104.1
	547	531	97.1
	228	250	109.6

#### DILUTION TEST

Sample	Dilution	Theoretical Concent. (pg/ml)	Measured Concent. (pg/ml)
Serum	1/1	-	966
	1/2	483	478
	1/4	241.5	247
	1/8	120.8	130
	1/16	60.4	54
	1/32	30	23

Samples were diluted with Specimen Diluent.

### 12.5 Time delay between last calibrator and sample dispensing

As shown hereafter, assay results remain accurate even when a sample is dispensed 30 minutes after the calibrators have been added to the coated wells.

#### TIME DELAY

sample	0 min	10 min	20 min	30 min	40 min
1	61	53	56	61	76
2	196	179	205	213	273
3	1584	1478	1433	1418	1533



**DRG® IL-6 ELISA (EIA- 4640)****REVISED 1 MAR. 2010 RM (VERS. 2.0)****RUO IN THE USA****13 INTERNAL QUALITY CONTROL**

If the results obtained for Control 1 and/or Control 2 are not within the range specified on the vial label, the results cannot be used unless a satisfactory explanation for the discrepancy has been given.

If desirable, each laboratory can make its own pools of control samples, which should be kept frozen in aliquots. Controls that contain azide will interfere with the enzymatic reaction and cannot be used.

Acceptance criteria for the difference between the duplicate results of the samples should rely on Good Laboratory Practises

It is recommended that controls be routinely assayed as unknown samples to measure assay variability. The performance of the assay should be monitored with quality control charts of the controls.

It is good practise to check visually the curve fit selected by the computer.

**14 REFERENCE INTERVALS**

These values are given only for guidance; each laboratory should establish its own normal range of values.

For guidance, the results of 34 serum samples from apparently healthy persons with low CRP levels, ranged between 0 and 50 pg/ml. 31 samples obtained values below 17 pg/ml.

**15 PRECAUTIONS AND WARNINGS****Safety**

For in vitro use only.

The human blood components included in this kit have been tested by European approved and/or FDA approved methods and found negative for HBsAg, anti-HCV, anti-HIV-1 and 2. No known method can offer complete assurance that human blood derivatives will not transmit hepatitis, AIDS or other infections. Therefore, handling of reagents, serum or plasma specimens should be in accordance with local safety procedures.

All animal products and derivatives have been collected from healthy animals. Bovine components originate from countries where BSE has not been reported. Nevertheless, components containing animal substances should be treated as potentially infectious.

Avoid any skin contact with all reagents, Stop Solution contains HCl. In case of contact, wash thoroughly with water.

Do not smoke, drink, eat or apply cosmetics in the working area. Do not pipette by mouth. Use protective clothing and disposable gloves.

**DRG<sup>®</sup> IL-6 ELISA (EIA- 4640)****REVISED 1 MAR. 2010 RM (VERS. 2.0)****RUO IN THE USA****16 BIBLIOGRAPHY**

1. HOUSSIAU F.A. et al., (1988) IL-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides.  
Arth. Rheum., 31:784-788.
2. MOSCOVITZ H. et al., (1994) Plasma cytokine determination in emergency department patients as predictor of bacteremia and infectious disease severity.  
Critical care Medicine, 22:1102-1107.
3. SAKAMOTO K. et al., (1994) Elevation of circulating interleukin 6 after surgery : factors influencing the serum level.  
Cytokine, 6:181-186.
4. KITA Y. et al., (1994) Evaluation of sequential serum interleukin-6 levels in liver allograft recipients.  
Transplantation, 57:1037-1041.
5. LE MOINE O. et al., (1994) Interleukin-6 : an early marker of bacterial infection in decompensated cirrhosis.  
J. of Hepatology, 20:819-824.

# **DRG® IL-6 ELISA (EIA- 4640)**

**REVISED 1 MAR. 2010 RM (VERS. 2.0)**

**RUO IN THE USA**

## **17 SUMMARY OF THE PROTOCOL**











	<b>CALIBRATORS (µl)</b>	<b>SAMPLE(S) CONTROLS (µl)</b>
Incubation buffer	50	50
Calibrators (0-5)	100	-
Samples, Controls	-	100
Incubate for 1 hour at room temperature with continuous shaking at 700 rpm. Aspirate the contents of each well. Wash 3 times with 400 µl of Wash Solution and aspirate.		
Anti-IL-6 -HRP conjugate	100	100
Specimen Diluent	50	50
Incubate for 1 hour at room temperature with continuous shaking at 700 rpm. Aspirate the contents of each well. Wash 3 times with 400 µl of Wash Solution and aspirate.		
Chromogenic Solution	200	200
Incubate for 15 min at room temperature with continuous shaking at 700 rpm.		
Stop Solution	100	100
Read on a microtiterplate reader and record the absorbance of each well at 450 nm (and 490 nm) versus 630 (or 650 nm)		

# DRG® IL-6 ELISA (EIA- 4640)

REVISED 1 MAR. 2010 RM (VERS. 2.0)

**RUO** IN THE USA

## SYMBOLS USED WITH DRG ASSAYS

Symbol	English	Deutsch	Français	Español	Italiano
	Consult instructions for use	Gebrauchsanweisung beachten	Consulter les instructions d'utilisation	Consulte las instrucciones de uso	Consultare le istruzioni per l'uso
	European Conformity	CE-Konformitätskennzeichnung	Conformité aux normes européennes	Conformidad europea	Conformità europea
	In vitro diagnostic device	In-vitro-Diagnostikum	Usage Diagnostic in vitro	Para uso Diagnóstico in vitro	Per uso Diagnostica in vitro
	For research use only	Nur für Forschungszwecke	Seulement dans le cadre de recherches	Sólo para uso en investigación	Solo a scopo di ricerca
	Catalogue number	Katalog-Nr.	Numéro de catalogue	Número de catálogo	Numero di Catalogo
	Lot. No. / Batch code	Chargen-Nr.	Numéro de lot	Número de lote	Numero di lotto
	Contains sufficient for <n> tests/	Ausreichend für "n" Ansätze	Contenu suffisant pour "n" tests	Contenido suficiente para <n> ensayos	Contenuto sufficiente per "n" saggi
	Storage Temperature	Lagerungstemperatur	Température de conservation	Temperatura de conservación	Temperatura di conservazione
	Expiration Date	Mindesthaltbarkeits-datum	Date limite d'utilisation	Fecha de caducidad	Data di scadenza
	Legal Manufacturer	Hersteller	Fabricant	Fabricante	Fabbricante
Distributed by	Distributor	Vertreiber	Distributeur	Distribuidor	Distributore
Content	Content	Inhalt	Conditionnement	Contenido	Contenuto
Volume/No.	Volume / No.	Volumen/Anzahl	Volume/Quantité	Volumen/Número	Volume/Quantità

Symbol	Portugues	Dansk	Svenska	Ελληνικά
	Consulte as instruções de utilização	Se brugsanvisning	Se bruksanvisningen	Εγχειρίδιο χρήστη
	Conformidade com as normas europeias	Europaeisk overensstemmelse	Europeisk överensstämmelse	Ευρωπαϊκή Συμμόρφωση
	Diagnóstico in vitro	In vitro diagnostik	Diagnostik in vitro	in vitro διαγνωστικό
	Catálogo n.º	Katalognummer	Katalog nummer	Αριθμός καταλόγου
	No do lote	Lot nummer	Batch-nummer	Αριθμός Παρτίδος
		Indeholder tilstrækkeligt til "n" test	Innehåller tillräckligt till "n" tester	Περιεχόμενο επαρκές για «n» εξετάσεις
	Temperatura de conservação	Opbevarings-temperatur	Förvaringstempratur	Θερμοκρασία αποθήκευσης
	Prazo de validade	Udløbsdato	Bäst före datum	Ημερομηνία λήξης
	Fabricante	Producent	Tillverkare	Κατασκευαστής
Content	Conteúdo	Indhold	Innehåll	Περιεχόμενο
Volume/No.	Volume/Número	Volumen/antal	Volym/antal	Όγκος/αριθ.